Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Cash from Operations (2024 - 2025)

Historic Cash from Operations for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to -$19.1 million.

  • Prelude Therapeutics' Cash from Operations rose 2997.14% to -$19.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$100.2 million, marking a year-over-year change of. This contributed to the annual value of -$102.9 million for FY2024, which is 389.96% up from last year.
  • According to the latest figures from Q3 2025, Prelude Therapeutics' Cash from Operations is -$19.1 million, which was up 2997.14% from -$26.1 million recorded in Q2 2025.
  • Prelude Therapeutics' 5-year Cash from Operations high stood at -$19.1 million for Q3 2025, and its period low was -$34.2 million during Q1 2025.